Unconjugated monoclonal antibodies that target hematopoietic differentiation antigens have been developed to treat hematologic malignancies. Although some of these have activity against chronic lymphocytic leukemia and hairy cell leukemia, in general, monoclonal antibodies have limited efficacy as single agents in the treatment of leukemia. To increase their potency, the binding domains of monoclonal antibodies can be attached to protein toxins. Such compounds, termed immunotoxins, are delivered to the interior of leukemia cells based on antibody specificity for cell surface target antigens. Recombinant immunotoxins have been shown to be highly cytotoxic to leukemic blasts in vitro, in xenograft model systems and in early phase clinical trials in humans. These agents will likely play an increasing role in the treatment of leukemia.
Introduction
A growing number of monoclonal antibodies (mabs) have been approved for the treatment of hematologic malignancies. 1 Newer constructs have been designed to improve activity, for example through the engineering of Fc domains with improved antibody-dependent cellular cytotoxicity (ADCC) function. Although some of these agents have activity against chronic lymphocytic leukemia (CLL) 2 and hairy cell leukemia (HCL), 3 in general, mabs have limited efficacy as single agents in the treatment of other leukemia subtypes. However, the binding domains of mabs, including variable fragments (Fvs) and antigen binding fragments (Fabs), can be utilized to deliver highly cytotoxic substances to cells that express cognate
antigens on their surface. Mab-based conjugates have been developed using plant and bacterial toxins, drugs and radioisotopes. This review focuses on the development of high molecular weight protein toxin conjugates to treat leukemia. (Antibody drug conjugates and radioimmunotherapy are reviewed elsewhere. 4, 5, 6 ) Toxin conjugates are attractive as anti-cancer agents because of the potency of their enzymatic domains. However, the clinical development of immunotoxins has been hindered by a variety of problems including poor antigen specificity, low cytotoxicity, nonspecific toxicities, immunogenicity and production difficulties. Many of these have been overcome through protein engineering and this review covers advances over the past 5 years.
Immunotoxin Structure
Immunotoxins have two primary components: targeting and killing moieties. Antibody fragments or whole antibodies may be employed for targeting and larger constructs have longer pharmacokinetic half-lives in comparison to Fv-based conjugates. Linkage options include gene fusions, peptide bonds, disulfide bonds and thioether bonds. Importantly, toxin attachment to the antibody must not interfere with antigen binding. Furthermore, the hybrid protein must remain intact while in the systemic circulation, but it must disassemble inside the target cell in order to
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Hematopoietic differentiation antigens and receptors that are expressed on the surface of leukemia cells are excellent targets provided they are not expressed on normal vital tissues.
( Table 1 ) Additionally, antigen targets must be internalized after mab binding in order for the immunotoxin to be transported intracellularly so that the toxin domain can mediate its cytotoxic action. (Fig. 1) Protein toxins are highly potent enzymes and only a small number of molecules need to be delivered to the site of action, the cell cytosol. 7 Once delivered, the turnover rate of the enzyme will allow many substrate molecules to be modified for each toxin molecule. Protein toxins can be attached directly to antibodies via peptide bonds and they can be modified easily through gene engineering, which is particularly useful when designing improved versions. 7 However, because toxins are foreign proteins, they can induce antibody formation. 4 Although this is a potential problem, as discussed below, protein engineering can be employed to modify immunogenic epitopes to reduce immunogenicity. Examples of clinically relevant immunotoxins that have undergone or are currently undergoing study in humans are provided in Table 1 . binding domain (e.g., at the N-terminus of PE and C-terminus of DT. (Fig. 2) The preferred construct of DT includes the first 388-389 amino acids followed by a cell-binding moiety. For PE-based immunotoxins, the Fv is followed by a toxin fragment that includes a processing domain followed by its ADP-ribosylating domain. For PE, but not DT, a C-terminal sequence that binds the KDEL receptor is needed for cytotoxic action. Ricin is not easily engineered into functional gene fusions. Therefore ricin-based immunotoxins rely on chemical conjugation of deglycosylated ricin A chain (dgA) to intact antibodies or Fabs. A variation on this theme attaches whole ricin, with its sugar binding sites blocked via chemical modification, to intact antibodies, thereby producing "blocked ricin" immunotoxins.
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Mechanism of Action
For immunotoxins to function as cytotoxic agents the molecule must first be internalized.
Importantly, the kinetics of internalization effect cytotoxicity and immunotoxins are generally more active when targeted to antigens that are efficiently internalized. 10 Inside the cell, the toxin must then be released and transported to the cytosol. Endosomes, lysosomes and the endoplasmic reticulum play critical roles in the fate of these molecules. However, unlike certain antibody-drug conjugates, 11, 12 protein toxins must stay intact and avoid lysosomal degradation. 13 Although the percentage of toxin trafficked to lysosomes has not been quantified, early studies of the delivery efficiency of PE indicated that approximately 4% of cell-associated toxin molecules reached the cytosol. 14 Deletion of most of domain II of PE, which contains several lysosomal cleavage sites, produces a protease-resistant immunotoxin with increased cytotoxic activity suggesting that this domain may contribute to inefficiencies of PE-based immunotoxins. 13 DT, specifically the diphtheria toxin A chain, translocates to the cytosol from acidic endosomes while PE-based molecules require a KDEL-like sequence to traffic to the endoplasmic reticulum from which it can then enter the cytosol. The ricin pathway to the cytosol more closely resembles the PE pathway than the DT one. 15 ( Fig. 1 and PE related proteins depend on a furin-like cleavage followed by the reduction of a key disulfide bond. 16, 17 In living cells, delivery to the appropriate intracellular location for toxin release appears to be a key factor in determining the effectiveness of the immunotoxin. For example, immunotoxins directed to CD22 are more potent than those to CD19 despite the fact that the number of cell-associated surface molecules is greater for CD19, related at least in part to more rapid CD22-mediated internalization.
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Immunotoxins in Clinical Trials
Targeting the interleukin-2 (IL2) receptor
The IL2 receptor complex, which consists of three subunits -α (CDβ5), (CD1ββ) and (CD132), is expressed on T-lymphocytes and natural killer cells. 18 Denileukin diftitox (DD) is a protein composed of interleukin (IL) 2 fused to the first 388 amino acids of diphtheria toxin.
Although it has IL2 instead of an Fv, it targets and functions like an immunotoxin. DD is approved for the treatment of cutaneous T cell lymphoma in adults and activity has been reported in other hematologic malignancies including IL2R expressing leukemias. 19 In a trial for patients with CLL where the levels of IL2 receptor are low, DD produced partial responses in only 2 of 18 (11%) patients. 20 DD binds tightly to the IL2 receptor three-chain complex, but less tightly to the α subunit, which is most commonly found at high levels on T cell malignancies. Newer constructs have been developed in attempt to target this lower affinity ILβ receptor α (CDβ5). antibody RFB4 is fused to PE38. 28 In the Phase I trial conducted in adults, 31 patients with HCL
showed an ORR of 81% with 61% CRs. 29 The dose limiting toxicity (DLT) was hemolytic uremic syndrome (HUS), which was completely reversible. To improve the activity of BL22, a modified agent with higher affinity was developed (moxetumomab pasudotox, HA22, CAT-8015) by mutating three amino acids in the Fv heavy chain CDR3 region from serine-serine-tyrosine (SSY) to threonine-histidine-tryptophan (THW). 33, 34 Twenty-eight adults with HCL were treated on a Phase I trial of moxetumomab pasudotox. 35 The agent was administered as a 30-minute IV infusion QOD x 3 with cycles repeated every 4 weeks at doses between 5 and 50 mcg/kg. 
immunotoxin HD37-dgA has been studied in combination with an anti-CD22 immunotoxin (see below).
Targeting CD19 and CD22
The combination of HD37-dgA and RFB4-dgA (Combotox) has been studied in adults and children with B-lineage hematologic malignancies. In a trial in children with ALL, 17 patients were treated and a MTD of 5 mg/m 2 was established. Three (18%) CRs were observed and hematologic activity was noted in other patients. There was a high incidence of severe adverse events and 2 of 11 (18%) developed anti-drug antibodies. 39 In a Phase I study in adults with ALL the MTD was 7 mg/m 2 with CLS as the DLT. One patient achieved a partial response and all patients demonstrated reduction in peripheral blasts. 40 A clinical trial of this agent in combination with cytarabine for adults with B-lineage ALL is in progress.
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A bivalent recombinant diphtheria-based immunotoxin has been developed in which one
Fv targets CD19 and the other CD22 (DT2219ARL). This agent has shown activity in preclinical models and is now in Phase I testing in adolescents and adults with B-lineage hematologic malignancies including ALL.
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Targeting CD3
CD3 is widely expressed in T cell malignancies. An anti-CD3 recombinant immunotoxin A-dmDT390-bisFv(UCHT1) is constructed of a divalent molecule consisting of two single chain antibody fragments reactive with the extracellular domain of CD3ε fused to the catalytic and translocation domains of DT. 43 This agent is in clinical trials for adults with T cell malignancies including leukemia.
Targeting CD33
CD33 is expressed on the surface of early multilineage hematopoietic progenitors, myelomonocytic precursors, cells of the monocyte/macrophage system, some lymphoid cells, 80-90% of cases of acute myeloid leukemia (AML) and some cases of B-cell precursor and T-ALL.
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Immunogenicity and anti-drug antibodies
Immunotoxins contain foreign proteins that can induce neutralizing antibody formation in patients with functional immunity. In our experience, the vast majority of individuals with solid tumors treated with protein immunotoxins have made anti-toxin antibodies after 1 or 2 cycles of treatment. 60 However, when immunotoxins are given to patients with hematologic malignancies, the incidence of anti-toxin antibody development is lower (15-50%) and commonly is not seen until multiple cycles of therapy are administered. For protein toxins to be useful over multiple cycles, especially in patients who are able to mount an immune response, immunogenicity needs to be reduced or suppressed. This can be accomplished in several ways including immunotoxin construct mutagenesis to remove immunodominant B and/or T cell epitopes and coadministration with immunosuppressive agents.
In the case of immunotoxins made from PE, we have been able to identify and remove immunodominant B cell epitopes recognized by the mouse immune system resulting in an active immunotoxin that can be given repeatedly to mice without inducing antibody formation. 61, 62 This was accomplished by mutation of specific large hydrophilic amino acids (Arg, Gln, Glu, Lys) to Ala, Ser, or Gly. Human B cell epitopes have also been mapped and silenced using a similar approach to that used to eliminate mouse epitopes. The major difference was that antibody phage display technology was used to isolate Fvs from human B cell RNA and the phage expressing Fvs used to map the epitopes. 63 A recombinant immunotoxin with modified human B cell epitopes is currently being developed by for the treatment of solid tumors.
Co-administration of immunosuppressive drugs can also effectively reduce the incidence of immunogenicity. 60 Such approaches to reduce immunogenicity will enable the use of immunotoxins at an earlier point in treatment when patients are less likely to be immunosuppressed.
Pharmacology
In general, the plasma half-life of immunotoxins in humans is relatively short ranging from approximately 30 minutes to 4 hours. Recombinant immunotoxins were originally designed to be small with the goal of enhancing penetration into solid tumor masses. 64 While small size may be useful it also causes these agents to be rapidly removed from the circulation. It is possible to make recombinant immunotoxins of larger size with improved pharmacology by fusing the toxin to Fabs or entire antibody molecules and producing these in E. coli. 65, 66 As indicated above, neutralizing anti-drug antibodies commonly develop and depending on the antibody titer, these can dramatically reduce immunotoxin levels. Notably, patients with pre-existing anti-toxin antibodies (e.g., from diphtheria vaccination or pseudomonas infection) can develop rapid anamnestic high-titer antibody responses after treatment with the associated immunotoxin. Clearance of peripheral blasts with persistence of bone marrow disease has been seen in patients treated with immunotoxins, 32, 39 raising the possibility of a protective effect within the marrow. Notably, incomplete immunotoxin-mediated cytotoxicity has been observed when ALL blasts are cultured on bone marrow stromal cells. 69 The bone marrow microenvironment could provide survival factors or trigger intracellular signaling pathways that might rescue blasts from immunotoxin-induced apoptosis. 70, 71 Anatomic factors related to densely packed marrow blasts could also confer resistance, for example through physical or pharmacological gradients against immunotoxin penetration, which might be offset by combination with chemotherapy.
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Reversible resistance to immunotoxin-mediated cytotoxicity in ALL cell lines has been established and demonstrated to be caused by methylation-induced silencing of diphthamide synthesis genes that prevents ADP-ribosylation of EF2. 73, 74 This can be prevented and reversed by epigenetic modifiers, which raises the prospect for efficacy of combination therapy if this Capillary leak syndrome. The incidence and severity of CLS associated with immunotoxins vary with the specific agent. In the case of ricin based immunotoxins this side effect has been attributed to carbohydrate residues on the toxin binding to endothelial cells, which has been diminished but not eliminated by using forms of ricin that do not contain carbohydrate modifications (i.e., deglycosylated). Further, a 3 amino acid motif in deglycosylated ricin toxin A contributes to CLS. While the modification of this sequence reduces pulmonary vascular leak in preclinical models, 76 this construct has not been tested in humans. In the case of PE based immunotoxins, CLS has only rarely been dose limiting, but this syndrome is nonetheless a significant side effect. In a pediatric Phase I trial of moxetumomab pasudotox, dose-limiting CLS was seen in 2 of 7 patients treated without corticosteroid prophylaxis, which seems to have been eliminated by the use of dexamethasone pre-treatment. 37 The efficacy of steroid prophylaxis against PE-induced CLS has been demonstrated in a pre-clinical model. 77 Weldon et al have reported on an immunotoxin that has a deletion of a large portion of domain II of PE that is fully cytotoxic yet its non-specific toxicities in mice, which may reflect the ability of these immunotoxins to cause CLS in patients, are greatly diminished.
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Hemolytic uremic syndrome. The occurrence of HUS has been reported in adults and children treated with immunotoxins. In most cases this has been reversible. 30 The mechanism of HUS development is unknown.
Summary
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